ICT 107

Drug Profile

ICT 107

Alternative Names: Cancer vaccine - ImmunoCellular Therapeutics; Dendritic cell vaccines - ImmunoCellular Therapeutics; ICT-107

Latest Information Update: 29 Nov 2016

Price : $50

At a glance

  • Originator ImmunoCellular Therapeutics
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Glioblastoma

Most Recent Events

  • 25 Jul 2016 ImmunoCellular Therapeutics receives regulatory approvals for a phase III trial in Glioblastoma Spain
  • 06 May 2016 ImmunoCellular Therapeutics receives regulatory approvals for a phase III trial in Glioblastoma, in Canada, the Netherlands and the United Kingdom
  • 01 Dec 2015 Phase-III clinical trials in Glioblastoma (Combination therapy, First-line therapy) in Canada (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top